LBP-014 HBsAg loss and seroconversion after 16-week or 24-week AHB-137 treatment in HBeAg-negative chronic hepatitis B participants on NA therapy: results from an ongoing multicenter, randomized phase IIb study
Yanhang Gao(Jilin University), Junqi Niu(Jilin University), Di Zhao(Wuhan Polytechnic University), Jinlin Hou(Southern Medical University), Xingbei Zhou, Guofeng Cheng, Haibing Gao(Fujian Medical University), Xinrui Wang, Chen Yang(Heidelberg University), Xieer Liang(Nanfang Hospital), Zhihong Liu, Miao Wang(Beijing Normal University), Hao Wang(Stevens Institute of Technology), Jidong Jia, Cheng Yong Yang, Youwen Tan(Jiangsu University), Hong Ma(Beijing Friendship Hospital), Shan Zhong, Huaxi Ma, Dachuan Cai(Dalian Medical University)
Cited by 2
Related Papers
Investigating the thermal runaway mechanisms of lithium-ion batteries based on thermal analysis database
|Applied Energy|2019|731
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346